Affix Medical is the next generation device for post-surgical drainage management. Over 5m surgeries per year in the US require drainage management of the post-surgical site. Unfortunately, legacy devices and techniques are inadequate in addressing the modern needs of these procedures, and are a main source of costly, yet preventable, complications.

The AffixClipTM is the new gold standard in post-surgical drainage management, which aims to reduce pain, dislodgement, and drain obstruction commonly associated with legacy devices. The AffixClipTM is currently on market are ready to scale.

Founded in 2011 on the South Side of Chicago, Lorenzo’s Frozen Pudding is a family-owned brand crafting gourmet frozen banana pudding and a variety of delicious signature flavors. Combining rich heritage with high-quality ingredients, Lorenzo’s delivers an elevated frozen dessert experience across retail, food service, and direct-to-consumer channels.

As the brand expands its presence, Lorenzo’s is scaling production through a dedicated Chicago co-manufacturing initiative to meet growing regional and national demand.

Joe & Bella is a Chicago-based adaptive apparel brand on a mission to make dressing easier, safer, and more dignified for older adults and people living with physical or cognitive challenges. Inspired by the founders’ personal experiences caring for aging loved ones, Joe & Bella combines innovative functionality with modern design to create clothing that people actually want to wear.

From magnetic button-down shirts that fasten with one hand to patented pants that simplify dressing and toileting, every product is thoughtfully designed to support independence without sacrificing personal style. Through direct-to-consumer sales and partnerships across healthcare, senior living, and retail, Joe & Bella is working to redefine what it means to dress well at every age.

Led by Scientific Founder Dr. Jon Odorico, an internationally recognized pancreatic transplant surgeon and regenerative medicine researcher, RMS has developed patented technology that transforms adult-derived induced pluripotent stem cells (iPSCs) into insulin-producing Islet-Like Clusters (ILCs). These clusters replicate the function of natural pancreatic islets, including the cells responsible for producing and regulating insulin.

RMS builds on groundbreaking stem cell discoveries pioneered at the University of Wisconsin–Madison by Dr. James Thomson, who first isolated human embryonic stem cells in 1998 and, in 2007, independently advanced the development of human induced pluripotent stem cells (iPSCs). That same year, Shinya Yamanaka published his landmark iPSC discovery, work that earned him the 2012 Nobel Prize in Physiology or Medicine. These breakthroughs transformed the possibilities of regenerative medicine and laid the scientific foundation for RMS’s next-generation stem cell technology.

By combining advanced stem cell engineering, immune protection and scalable manufacturing, RMS is working to restore the body’s natural ability to produce insulin and fundamentally change the treatment of Type 1 and Type 2 diabetes.

Raising capital is hard. Diligence shouldn’t be. Locker is verified information, organized and ready to share including ten balance sheet ratios, flags, bad actor checks on covered persons. If a company is raising capital, planning to raise capital or thinks they will sell their business someday….they need a Locker today.

The company was founded by a proven tech entrepreneur and operator with multiple exits who decided it was time to make diligence better for everyone. Locker has been built and rebuilt multiple times after extensive testing and revenue. It is ready for market and seeking $1.2M in operating capital.

Circuit boards are in every electronic device, from phones to fighter jets. Yet circuit board manufacturing has left the U.S., which now makes only 4% of the world’s bare board supply. This is due to the conventional process being expensive to run here. It requires a long line of specialized equipment, industrial chemicals and acids, wastewater treatment, permitting, and skilled labor; and it has barely changed in decades. uFab has replaced that process with a patented, laser-based system that condenses the traditional multi-million-dollar production line into a single machine with no chemical etching.

By eliminating chemical waste handling, digitizing and simplifying production, and reducing capital costs, we can produce circuit boards domestically at price parity with Asian manufacturers. uFab’s goal is to rebuild domestic circuit board manufacturing on this technology platform, from defense programs that need a secure supply, to the high-volume commercial work that moved offshore decades ago, to high-tech emerging industries like physical AI and data center hardware.